Describe the EVEREST trial to me

According to the NCCN Guidelines for Kidney Cancer (2023), the EVEREST trial was a Phase 3 randomized study that evaluated everolimus as adjuvant therapy for patients with renal cell carcinoma (RCC) who had undergone nephrectomy.

Key points from ASCO Clinical Practice Guidelines:

• The trial studied patients with high-risk RCC who had undergone complete surgical removal of their kidney tumor
• Patients were randomized to receive either: • Everolimus (an mTOR inhibitor) • Placebo
• The primary goal was to evaluate if everolimus could prevent or delay cancer recurrence

However, it's important to note that according to the National Cancer Institute (NCI), the trial results did not show a significant improvement in disease-free survival with everolimus compared to placebo. As a result, everolimus is not currently FDA-approved or recommended as adjuvant therapy for kidney cancer patients after surgery.

The current NCCN Guidelines do not recommend routine use of everolimus in the adjuvant setting based on these results. Instead, other treatments like pembrolizumab or adjuvant targeted therapy may be recommended for high-risk patients after surgery.

Always discuss your specific treatment options with your oncology team, as they can best determine what treatment approach is most appropriate for your individual case.